{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-002448","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.724396+00:00","generated_at":"2026-05-27T23:42:24.101947+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Protagenic Therapeutics gets Nasdaq notice for missing annual meeting; sets Feb 21, 2025 meeting","bullets":["Received Nasdaq notice on Jan 15, 2025 for failing to hold annual meeting within 12 months of FY 2023 end (Listing Rule 5620(a)).","Company has scheduled annual meeting to occur no later than February 21, 2025 to regain compliance.","No immediate effect on listing of PTIX or PTIXW on Nasdaq Capital Market.","Will submit matter to Nasdaq Hearings Panel as part of ongoing listing discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-002448","json":"https://secwatch.observer/filing/0001493152-25-002448.json","markdown":"https://secwatch.observer/filing/0001493152-25-002448.md","text":"https://secwatch.observer/filing/0001493152-25-002448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T23:42:24.101947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc67d2813ee1493d93d4b5c853e19dfd20d2504a","claim":"Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).","evidence_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-025087","ticker":"LASE","company_name":"Laser Photonics Corp","filed_at":"2026-05-22T21:27:31+00:00","headline":"Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025087","json":"https://secwatch.observer/filing/0001493152-26-025087.json","markdown":"https://secwatch.observer/filing/0001493152-26-025087.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"received a notice from Nasdaq Listing Qualifications\ndepartment of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q\nfor the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated\nthat the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception\nto allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or\nNovember 16, 2026. A\ncopy of t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm"}},{"accession":"0002001557-26-000118","ticker":"INV","company_name":"Innventure, Inc.","filed_at":"2026-05-19T21:45:13+00:00","headline":"Innventure regains Nasdaq compliance after appointing Bruce Brown to Audit Committee","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002001557-26-000118","json":"https://secwatch.observer/filing/0002001557-26-000118.json","markdown":"https://secwatch.observer/filing/0002001557-26-000118.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/0002001557-26-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/innv-20260515.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"April 30, 2026, following the resignation of Daniel Hennessy from the Company’s Board of Directors (the “Board”) and Audit Committee effective April 29, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/0002001557-26-000118-index.htm"}},{"accession":"0001823878-26-000034","ticker":"MYPS","company_name":"PLAYSTUDIOS, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"PLAYSTUDIOS receives Nasdaq Capital Market transfer; second compliance period to Nov 2, 2026","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001823878-26-000034","json":"https://secwatch.observer/filing/0001823878-26-000034.json","markdown":"https://secwatch.observer/filing/0001823878-26-000034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823878/000182387826000034/0001823878-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823878/000182387826000034/myps-20260505.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"May 5, 2026, Nasdaq staff approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The transfer will become effective at the opening of business on May 6, 2026 (the “Transfer Date”) and wi","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1823878/000182387826000034/0001823878-26-000034-index.htm"}},{"accession":"0001628280-26-029106","ticker":"GREE","company_name":"Greenidge Generation Holdings Inc.","filed_at":"2026-05-01T23:59:59+00:00","headline":"Greenidge receives Nasdaq notice for audit committee non-compliance after director resignation","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-029106","json":"https://secwatch.observer/filing/0001628280-26-029106.json","markdown":"https://secwatch.observer/filing/0001628280-26-029106.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844971/000162828026029106/0001628280-26-029106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844971/000162828026029106/gree-20260429.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"April 29, 2026, the Company received a notice from Nasdaq (the “Notice”) confirming the Company’s non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) as a result of Mr. Fearn’s resignation from the Audit Committee. As","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1844971/000162828026029106/0001628280-26-029106-index.htm"}},{"accession":"0001493152-26-019328","ticker":"ARAI","company_name":"Arrive AI Inc.","filed_at":"2026-04-28T23:59:59+00:00","headline":"Arrive AI regains compliance with Nasdaq MVPHS rule; delisting notice closed","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019328","json":"https://secwatch.observer/filing/0001493152-26-019328.json","markdown":"https://secwatch.observer/filing/0001493152-26-019328.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818274/000149315226019328/0001493152-26-019328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818274/000149315226019328/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"March 31, 2026, Arrive AI Inc. (the “ Company ”) received a letter from The Nasdaq Listing Qualifications Department\n(the “ Staff ”) indicating that the Company’s common stock had failed to maintain a minimum market valu","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1818274/000149315226019328/0001493152-26-019328-index.htm"}},{"accession":"0001213900-26-063806","ticker":"ILLR","company_name":"Triller Group Inc.","filed_at":"2026-06-02T12:26:59+00:00","headline":"Triller gets Nasdaq bid-price exception until June 30, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063806","json":"https://secwatch.observer/filing/0001213900-26-063806.json","markdown":"https://secwatch.observer/filing/0001213900-26-063806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/ea0292925-8k_triller.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"May 29, 2026, the Nasdaq Hearings Panel (the\n“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant\nTriller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,\n2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following\na successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which\nmodified a previous December 26, 2025 decision by a Nasdaq Hearings Panel","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm"}},{"accession":"0001213900-26-063575","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-06-01T21:00:15+00:00","headline":"iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063575","json":"https://secwatch.observer/filing/0001213900-26-063575.json","markdown":"https://secwatch.observer/filing/0001213900-26-063575.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/ea0292875-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"May 29, 2026, iSpecimen Inc. (the “Company”)\nreceived a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum\nof $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report\non Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May\n29, 2026, the Company doe","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications\ndepartment (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}